期刊
MODERN RHEUMATOLOGY
卷 31, 期 1, 页码 141-150出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14397595.2020.1751402
关键词
Anti-fibrotic; interstitial lung disease; nintedanib; SSc-ILD; scleroderma
类别
资金
- Boehringer Ingelheim
- Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
Nintedanib demonstrated efficacy in Japanese patients with SSc-ILD, showing a slower decline in FVC compared to placebo over 52 weeks. There was no heterogeneity detected in treatment effect between Japanese and non-Japanese patients, and the safety profile of nintedanib in Japanese patients was similar to that in patients with idiopathic pulmonary fibrosis.
Objective: We examined the efficacy and safety of nintedanib in Japanese patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the global Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial. Methods: Randomised patients received oral nintedanib 150 mg (N = 34) twice daily or placebo (N = 36) until the last patient reached 52 weeks of treatment (up to 100 weeks). Data were analysed using a subgroup analysis model with Japanese and non-Japanese patients as subgroup variables. Results: In Japanese patients, the adjusted annual rate of forced vital capacity (FVC) decline over 52 weeks was -86.2 mL/year (nintedanib) and -90.9 mL/year (placebo); treatment difference, 4.67 mL/year (95% confidence interval, -103.28, 112.63). Treatment effect heterogeneity between Japanese and non-Japanese patients was not detected (treatment-by-visit-by-subgroup interaction; p = .49). FVC decline was smaller for nintedanib versus placebo through 100 weeks in Japanese patients. The most commonly reported adverse events with nintedanib were gastrointestinal and liver disorder events; most were mild-to-moderate in severity. Conclusion: In both Japanese and non-Japanese patients with SSc-ILD, nintedanib slowed the progression of ILD, with no heterogeneity detected between the subgroups. The safety profile for nintedanib in Japanese patients was similar to that observed in patients with idiopathic pulmonary fibrosis (ClinicalTrials.gov: NCT02597933).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据